Hepion Pharmaceuticals Faces Delisting Notice

Ticker: CTRVP · Form: 8-K · Filed: Apr 17, 2025 · CIK: 1583771

Hepion Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyHepion Pharmaceuticals, Inc. (CTRVP)
Form Type8-K
Filed DateApr 17, 2025
Risk Levelhigh
Sentimentbearish

Sentiment: bearish

Topics: delisting, listing-standards, regulatory

TL;DR

Hepion Pharmaceuticals got a notice about failing to meet listing rules - stock might be delisted.

AI Summary

Hepion Pharmaceuticals, Inc. filed an 8-K on April 17, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company, formerly known as ContraVir Pharmaceuticals, Inc., is incorporated in Delaware and has its principal executive offices in Morristown, NJ.

Why It Matters

This filing indicates potential issues with Hepion Pharmaceuticals' continued listing on an exchange, which could significantly impact its stock value and trading accessibility.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued operation and investor confidence.

Key Players & Entities

  • Hepion Pharmaceuticals, Inc. (company) — Registrant
  • ContraVir Pharmaceuticals, Inc. (company) — Former company name
  • April 15, 2025 (date) — Earliest event reported
  • April 17, 2025 (date) — Date of report
  • Delaware (jurisdiction) — State of incorporation
  • Morristown, NJ (location) — Principal executive offices

FAQ

What specific listing rule or standard has Hepion Pharmaceuticals failed to satisfy?

The filing does not specify the exact rule or standard that Hepion Pharmaceuticals has failed to satisfy, only that a notice has been received.

What is the potential consequence of failing to satisfy a continued listing rule?

The potential consequence is delisting from the stock exchange where the company's securities are traded.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on April 15, 2025.

What was Hepion Pharmaceuticals' former company name?

Hepion Pharmaceuticals, Inc. was formerly known as ContraVir Pharmaceuticals, Inc.

Where are Hepion Pharmaceuticals' principal executive offices located?

Hepion Pharmaceuticals' principal executive offices are located at 55 Madison Ave., Suite 400-PMB# 4362, Morristown, NJ 07960.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 17, 2025 regarding Hepion Pharmaceuticals, Inc. (CTRVP).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.